Magnesium in Prevention and Therapy
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
Dysmagnesemia in Covid-19 Cohort Patients: Prevalence and Associated Factors
Magnesium Research 2020; 33 (4): 114-122 ORIGINAL ARTICLE Dysmagnesemia in Covid-19 cohort patients: prevalence and associated factors Didier Quilliot1, Olivier Bonsack1, Roland Jaussaud2, Andre´ Mazur3 1 Transversal Nutrition Unit and; 2 Internal Medicine and Clinical Immunology. Nancy University Hospital, University of Lorraine, France; 3 Universite´ Clermont Auvergne, INRAE, UNH, Unite´ de Nutrition Humaine, Clermont-Ferrand, France Correspondence <[email protected]> Abstract. Hypomagnesemia and hypermagnesemia could have serious implications and possibly lead to progress from a mild form to a severe outcome of Covid-19. Susceptibility of subjects with low magnesium status to develop and enhance this infection is possible. There is little data on the magnesium status of patients with Covid-19 with different degrees of severity. This study was conducted to evaluate prevalence of dysmagnesemia in a prospective Covid-19 cohort study according to the severity of the clinical manifestations and to identify factors associated. Serum magnesium was measured in 300 of 549 patients admitted to the hospital due to severe Covid-19. According to the WHO guidelines, patients were classified as moderate, severe, or critical. 48% patients had a magnesemia below 0.75 mmol/L (defined as magnesium deficiency) including 13% with a marked hypomagnesemia (<0.65 mmol/L). 9.6% had values equal to or higher than 0.95 mmol/L. Serum magnesium concentrations were significantly lower in female than in male (0.73 Æ 0.12 vs 0.80 Æ 0.13 mmol/L), whereas the sex ratio M/F was higher in severe and critical form (p<0.001). In a bivariate analysis, the risk of magnesium deficiency was significantly and negatively associated with infection severity (p<0.001), sex ratio (M/F, p<0.001), oxygenotherapy (p<0.001), stay in critical care unit (p=0.028), and positively with nephropathy (p=0.026). -
Buffered Mag Glycinate W L-Taurine P.Pub
Magnesium BisGlycinate TM buffered w/L-Taurine 90 Veggie Capsules NPN80026983 Matrix Nutritional Series Cardiac, Neurological & Musculo-Skeletal Support Matrix Nutritionals Series was designed as an eclectic offering for the Physica Energetics line of remedies primarily to assist in the “reactivation of the mesenchyme” (Dr. Reinhold Voll), via the nutritional complement pathways. These pathways are present in every system throughout the body and require balanced attention. In keeping with the principles of BioEnergetic Medicine, the remedies nourish and support these systems without punishing them with overstimulation or imbalancing factors, which, ultimately, is counterproductive. This approach has been carefully and respectfully designed to provide the necessary natural (organic where available), synergistic factors in proper energetic and biochemical ratios, to ensure assistance towards yielding a deep and lasting result. They are not to be confused with replacement therapy nutraceuticals that may seem to help for the moment, until the patient stops taking them or the condition is driven deeper. These remedies honour The Legacy of BioEnergetic Medicine, and are known by both patient and practitioner to be exceptionally effective. In 2006, the World Health Organization reached consensus experience twitches (in the eyelids as well!), cramps, muscle that a majority of the world's population is magnesium tension, muscle soreness, including back aches, neck pain, deficient. Likewise, in 1995, the Gallop Organization conducted a tension headaches and jaw joint (or TMJ) dysfunction. Also, one survey and found that 95% of adult Americans are magnesium may experience chest tightness or a peculiar sensation that one deficient! can't take a deep breath. Sometimes a person may sigh a lot. -
The Importance of Minerals in the Long Term Health of Humans Philip H
The Importance of Minerals in the Long Term Health of Humans Philip H. Merrell, PhD Technical Market Manager, Jost Chemical Co. Calcium 20 Ca 40.078 Copper 29 Cu 63.546 Iron Magnesium 26 12 Fe Mg 55.845 24.305 Manganese Zinc 25 30 Mn Zn 55.938 65.380 Table of Contents Introduction, Discussion and General Information ..................................1 Calcium ......................................................................................................3 Copper .......................................................................................................7 Iron ...........................................................................................................10 Magnesium ..............................................................................................13 Manganese ..............................................................................................16 Zinc ..........................................................................................................19 Introduction Daily intakes of several minerals are necessary for the continued basic functioning of the human body. The minerals, Calcium (Ca), Iron (Fe), Copper (Cu), Magnesium (Mg), Manganese (Mn), and Zinc (Zn) are known to be necessary for proper function and growth of the many systems in the human body and thus contribute to the overall health of the individual. There are several other trace minerals requirements. Minimum (and in some cases maximum) daily amounts for each of these minerals have been established by the Institute of -
Subject: Manufacturing of Synthetic Organic Chemicals (API's: 400Kg
Subject: Manufacturing of Synthetic Organic Chemicals (API’s: 400Kg/day + R&D: 33.3Kg/day) at Plot No. 4, Industrial Park, Attivaram Village, Ozili Mandal, SPSR Nellore District, Andhra Pradesh by M/s. Balaji Chirex Pvt. Ltd., - reg. Project proposal: M/s. Balaji Chirex Pvt. Ltd., proposed to establish a Synthetic Organic Chemical Manufacturing Unit at Plot No. 4, Industrial Park, Attivaram Village, Ozili Mandal, SPSR Nellore District, Andhra Pradesh. The company acquired 4.515 acres of land for the proposed plant and allocated 1.49 acres of the area for green belt. The site is surrounded by internal IDA road in north direction, Shimoga Life Sciences Pvt. Ltd., in east direction and open plots in south and west directions. The nearest human settlement from the site is Attivaram village located at distance of 1.1 km from the site. Mamidi Kalva is at a distance of 4.28 km in southwest direction, flowing from northeast to southwest. Attivaram RF at a distance of 0.5 Km in east, Jayampu RF at a distance of 7 Km in northwest, Permidi RF at a distance of 5 Km in southwest and Sangavaram RF at a distance of 4.5 Km in southwest directions respectively. There are no national parks or sanctuaries within 10 km radius of the site. Total capital cost of the project is Rs. 5 Crores. Manufacturing capacity is presented as follows; Manufacturing Capacity S.No Name of the Product Capacity Kg/Month Kg/Day 1 Alfuzosin 50 1.7 2 Allantion 200 6.7 3 Aripiprazole 100 3.3 4 Calcium Ascorbate 500 16.7 5 Calcium Aspartate 1000 33.3 6 Calcium Citrate Malate 2000 -
Oral Magnesium Gly Magnesium Glycerophosphate Ceroph
pat hways Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate Evidence summary Published: 29 January 2013 nice.org.uk/guidance/esuom4 Key points from the evidence The content of this evidence summary was up-to-date in January 2013. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Magnesium glycerophosphate is a magnesium salt that is available as a tablet, capsule, liquid solution or liquid suspension for oral use. The British national formulary (BNF) states that oral magnesium glycerophosphate is a suitable preparation to prevent recurrence of symptomatic hypomagnesaemia in people who have already been treated for this condition. This evidence summary looks at the use of oral magnesium glycerophosphate in patients who have previously been treated with an intravenous infusion of magnesium. Oral magnesium glycerophosphate does not have UK marketing authorisation for this or any other indication, and therefore it is an unlicensed medicine in the UK. No published clinical trials comparing the efficacy of oral magnesium glycerophosphate with placebo or any form of active treatment for preventing recurrent hypomagnesaemia after treatment with intravenous magnesium were identified. The only videncee found was from 3 case reports describing the use of oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia in adults after intravenous treatment. © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- Page 1 of conditions#notice-of-rights). 17 Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4) Two of the 3 case reports concerned patients who had short bowel syndrome due to surgical resection. -
Marketing Research on Dietary Supplements for Periodontitis in Patient Diabetes
Original Study MARKETING RESEARCH ON DIETARY SUPPLEMENTS FOR PERIODONTITIS IN PATIENT DIABETES Galyna Biloklytska, Svitlana Viala, Alina Koval* National Medical Academy of Postgraduate Education named after P. L. Shupyk, Kyiv, Ukraine. ABSTRACT The vast majority of periodontal diseases are inflammatory and can develop under the influence of both local causes and the combined action of common (endogenous) and local factors against the background of changes in the reactivity of the body. In the pathogenesis of the development of periodontal diseases in patients with diabetes, the main role is given to angiopathies. Since periodontitis is characterized by various vascular disorders, which are largely similar to diabetic angiopathy, it is not easy to prove the presence of the latter with periodontitis. So some authors argue this, while, others deny it. The starting point of diabetic microangiopathies is a violation of carbohydrate metabolism, as well as a violation of glycosamine metabolism, which determines the functional and structural integrity of the vascular basement membrane. Key words: producing countries, periodontitis, diabetes mellitus, dietary supplements, medicines, dentistry. Introduction the treatment and prevention of such pathology, as periodontitis in patients with diabetes. Nowadays, the problem of treatment and rehabilitation of patients with periodontitis is quite actual, as there is an The search for modern drugs and perspective combinations increase in morbidity among people of working age, of microelements for treatment, both internally and locally, increasing demands on appearance as a factor that plays an using applications on periodontal tissues in patients with important role in professional and personal success in various types of diabetes, involves marketing analysis of society. -
Increased Mortality Associated with Hypermagnesemia in Severe COVID-19 Illness
Original Investigation Increased Mortality Associated with Hypermagnesemia in Severe COVID-19 Illness Jacob S. Stevens 1,2, Andrew A. Moses1, Thomas L. Nickolas1,2, Syed Ali Husain1,2, and Sumit Mohan1,2,3 Key Points Hypermagnesemia is common in patients admitted with coronavirus disease 2019. The development of hypermagnesemia in coronavirus disease 2019 is associated with renal failure and markers of high cell turnover. In adjusted models, patients who develop hypermagnesemia have an increased risk of mortality. Abstract Background Although electrolyte abnormalities are common among patients with COVID-19, very little has been reported on magnesium homeostasis in these patients. Here we report the incidence of hypermagnesemia, and its association with outcomes among patients admitted with COVID-19. Methods We retrospectively identified all patients with a positive test result for SARS-CoV-2who were admitted to a large quaternary care center in New York City in spring 2020. Details of the patients’ demographics and hospital course were obtained retrospectively from medical records. Patients were defined as having hypermagnesemia if their median magnesium over the course of their hospitalization was .2.4 mg/dl. Results A total of 1685 patients hospitalized with COVID-19 had their magnesium levels checked during their hospitalization, and were included in the final study cohort, among whom 355 (21%) had hypermagnesemia. Patients who were hypermagnesemic had a higher incidence of shock requiring pressors (35% vs 27%, P,0.01), respiratory failure requiring mechanical ventilation (28% vs 21%, P50.01), AKI (65% vs 50%, P,0.001), and AKI severe enough to require renal replacement therapy (18% vs 5%, P,0.001). -
Magnesium Sulfate for Neuroprotection Practice Guideline
[Type text] [Type text] Updated June 2013 Magnesium Sulfate for Neuroprotection Practice Guideline I. Background: Magnesium sulfate has been suggested to have neuro-protective effect in retrospective studies from 1987 and 1996. Since that time three randomized control trials have been performed to assess magnesium therapy for fetal neuroprotection. These studies have failed to demonstrate statistically significant decrease in combined outcome of cerebral palsy and death or improved overall neonatal survival. However, these results did demonstrate a significant decrease in cerebral palsy of any severity by 30%, particularly moderate-severe cerebral palsy (40-45%). The number needed to treat at less than 32 weeks gestation is 56. The presumptive mechanism of action for magnesium sulfate focuses on the N-methyl-D-aspartate receptor. Additional magnesium effects include calcium channel blockade resulting in cerebrovascular relaxation and magnesium mediated decreases in free radical production and reductions in the production of inflammatory cytokines. Magnesium sulfate should not be used as a tocolytic simply because of the potential for neuro-protective effects. In a recent committee opinion, ACOG states “the available evidence suggests that magnesium sulfate given before anticipated early preterm birth reduces the risk of cerebral palsy in surviving infants” but specific guidelines should be established. “The U.S. FDA has recently changed the classification of magnesium sulfate injection from Category A to Category D. However, this change was based on a small number of neonatal outcomes in cases in which the average duration of exposure was 9.6 weeks. The ACOG Committee on Obstetric Practice and the Society for Maternal-Fetal Medicine continue to support the use of magnesium sulfate in obstetric care for appropriate conditions and for appropriate, short term (usually less than 48 hours) durations of treatment.” II. -
Early-Onset Neonatal Hyperkalemia Associated with Maternal
Tanaka et al. BMC Pediatrics (2018) 18:55 https://doi.org/10.1186/s12887-018-1048-4 CASEREPORT Open Access Early-onset neonatal hyperkalemia associated with maternal hypermagnesemia: a case report Kenichi Tanaka1, Hiroko Mori1, Rieko Sakamoto2, Shirou Matsumoto2, Hiroshi Mitsubuchi1, Kimitoshi Nakamura2 and Masanori Iwai1* Abstract Background: Neonatal nonoliguric hyperkalemia (NOHK) is a metabolic abnormality that occurs in extremely premature neonates at approximately 24 h after birth and is mainly due to the immature functioning of the sodium (Na+)/potassium (K+) pump. Magnesium sulfate is frequently used in obstetrical practice to prevent preterm labor and to treat preeclampsia; this medication can also cause hypermagnesemia and hyperkalemia by a mechanism that is different from that of NOHK. Herein, we report the first case of very early-onset neonatal hyperkalemia induced by maternal hypermagnesemia. Case presentation: A neonate born at 32 weeks of gestation developed hyperkalemia (K+ 6.4 mmol/L) 2 h after birth. The neonate’s blood potassium concentration reached 7.0 mmol/L 4 h after birth, despite good urine output. The neonate and his mother had severe hypermagnesemia caused by intravenous infusion of magnesium sulfate given for tocolysis due to pre-term labor. Conclusion: The early-onset hyperkalemia may have been caused by the accumulation of potassium ions transported through the placenta, the shift of potassium ions from the intracellular to the extracellular space in the infant due to the malfunctioning of the Na+/K+ pump and the inhibition of renal distal tube potassium ion secretion, there is a possibility that these mechanisms were induced by maternal and fetal hypermagnesemia after maternal magnesium sulfate administration. -
Calcium Gluconate
CALCIUM GLUCONATE CLASSIFICATION Minerals and electrolytes TRADE NAME(S) Calcium Gluconate 10% (for IV use) Calcium Gluconate gel 2.5% (for topical use) DESIRED EFFECTS Lower potassium levels; pain relief and neutralizing fluoride ion MECHANISM OF ACTION Calcium is the primary component of skeletal tissue. Bone serves as a calcium depot and as a reservoir for electrolytes and buffers. INDICATIONS Suspected hyperkalemia in adult PEA/Asystole Antidote for calcium channel blocker overdose and magnesium sulfate toxicity Gel is used for hydrofluoric acid burns Suspected hyperkalemia with adult crush injury or peaked T-waves on EKG CONTRAINDICATIONS Should not be given to patients with digitalis toxicity Should be used with caution in patients with dehydration ADVERSE REACTIONS When given too rapidly or to someone on digitalis, can cause sudden death from ventricular fibrillation May cause mild to severe IV site irritation SPECIAL CONSIDERATIONS Must either use a different IV line or flush line with copious normal saline if being given with sodium bicarbonate. When used on hydroflouric acid burns, relief of pain is the only indication of treatment efficacy. Therefore, use of analgesic agents is not recommended. DOSING REGIMEN Suspected hyperkalemia in adult PEA/asystole or adult crush injury, or evidence of EKG changes (Ex. peaked T-waves) o Calcium gluconate 10% 15-30 ml IV/IO over 2-5 minutes KNOWN calcium channel blocker overdose - administer 3 grams IV/IO may repeat dose in 10 minutes if no effect. Hydrofluoric acid burns apply calcium gluconate gel 2.5% every 15 minutes to burned area and massage continuously until pain disappears. -
The Best Ingredients for a Better Life #Faravellinutradivision
The Best ingredients for a better life #FaravelliNutraDivision INGREDIENTS FOR THE FOOD SUPPLEMENTS INDUSTRY PRODUCT LIST MINERAL SALTS • L-CARNITINE HCL • AMMONIUM BICARBONATE • L-CARNITINE TARTRATE • AMMONIUM CARBONATE • L-CYSTEINE BASE DAB 10 • AMMONIUM CHLORIDE BP/USP/DAB/E510 • L-CYSTEINE, MONOHYDRATE HCL, • CALCIUM ACETATE ANHYDROUS AND BASE • CALCIUM CARBONATE • L-GLUTAMIC ACID • CALCIUM GLUCONATE ORAL • L-GLUTAMINE • CALCIUM GLYCEROPHOSPHATE BPC • L-ISOLEUCINE • CALCIUM LACTATE GLUCONATE • L-LEUCINE STANDARD & BY FERMENTATION • CALCIUM LACTATE USP XXIII/PH EUR/FCC • L-LYSINE HCL • CALCIUM PIDOLATE • L-METHIONINE • CHROMIUM PICOLINATE 10% • L-SERINE • CHROMIUM YEAST • L-THEANINE • COPPER BISGLYCINATE • L-TYROSINE • COPPER GLUCONATE • L-VALINE • DISODIUMACETATE • TAURINE WITH & WITHOUT ANTICACKING • IRON GLUCONATE EP • IRON OROTATE NATURAL EXTRACTS • MAGNESIUM ASCORBATE • CHROMIUM YEAST • MAGNESIUM GLUCONATE • ECHINACEA EXTRACT • MAGNESIUM GLYCEROPHOSPHATE • SELENIUM YEAST • MAGNESIUM LACTATE DIHYDRATE • WHITE TEA EXTRACT • MAGNESIUM OROTATE • ZINC YEAST • MAGNESIUM PIDOLATE • MANGANESE BISGLYCINATE PROTEINS • MANGANESE GLUCONATE • SOY PROTEIN ISOLATE • POTASSIUM ACETATE BP 80 • PEA PROTEIN ISOLATE • POTASSIUM CITRATE TRIBASIC MONOHYDRATE • POTASSIUM GLUCONATE VITAMINS • POTASSIUM IODIDE • MIXED TOCOPHEROLS 70% OIL • POTASSIUM IODATE • NATURAL TOCOPHEROLS • PRECIPITATED CALCIUM CARBONATE PH EUR • SODIUM ASCORBATE • SELENIUM YEAST • TOCOTRIENOLS • SODIUM ACETATE ANHYDRATH, TRIHYDRATE • VITAMIN B1 HCL • ZINC BISGLYCINATE • VITAMIN -
Estonian Statistics on Medicines 2016 1/41
Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole